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Parkinson’s disease (PD) is a neurological disorder characterized by the manifestation of
motor symptoms, such as akinesia, muscle rigidity and tremor at rest. These symptoms
are classically attributed to the degeneration of dopamine neurons in the pars compacta
of substantia nigra (SNc), which results in a marked dopamine depletion in the striatum.
It is well established that dopamine neurons in the SNc innervate not only the striatum,
which is the main target, but also other basal ganglia nuclei including the two segments of
globus pallidus and the subthalamic nucleus (STN). The role of dopamine and its depletion
in the striatum is well known, however, the role of dopamine depletion in the pallidal
complex and the STN in the genesis of their abnormal neuronal activity and in parkinsonian
motor deficits is still not clearly determined. Based on recent experimental data from
animal models of Parkinson’s disease in rodents and non-human primates and also from
parkinsonian patients, this review summarizes current knowledge on the role of dopamine
in the modulation of basal ganglia neuronal activity and also the role of dopamine depletion
in these nuclei in the pathophysiology of Parkinson’s disease.
Keywords: dopamine, extrastriatal dopamine, basal ganglia, globus pallidus, subthalamic nucleus, Parkinson’s
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INTRODUCTION
Parkinson’s disease (PD) is a neurological disorder character-
ized by the manifestation of motor symptoms such as akinesia,
muscle rigidity and tremor at rest. These motor deficits are
classically attributed to the degeneration of dopamine neurons
in the pars compacta of substantia nigra (SNc), which result
in a marked dopamine depletion in the striatum, the primary
projection region of the SNc. Furthermore, it is well established
now that dopamine neurons in the SNc innervate not only the
striatum but also other basal ganglia nuclei including the two
segments of globus pallidus, the external part (GPe in primate,
the equivalent of GP in rodents) and the internal part (GPi in
primate, the equivalent of entopeduncular nucleus in rodents),
as well as the subthalamic nucleus (STN; Smith and Villalba,
2008). Dopamine has been shown to modulate the neuronal
electrical activity of all these basal ganglia nuclei (Rommelfanger
and Wichmann, 2010).
Dopamine cell degeneration in the pathophysiology of PD
is considered as the main hallmark of the disease (Agid and
Blin, 1987; Hornykiewicz, 1998). Indeed, dopamine depletion
by stereotaxic injection of 6-hydroxydopamine (6-OHDA) in
the rat or by systemic injections of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) in the non-human primate resulted
in alterations of the firing rate and/or patterns of GPe, GPi and
STN neurons. The tonic regular pattern in the normal condition
changed toward a pathological exaggerated burst firing with oscil-
lations after dopamine cell lesions in the substantia nigra (SNc;
Albin et al., 1989; DeLong, 1990; Bergman et al., 1994; Wichmann
et al., 1994; Boraud et al., 1998; Ni et al., 2000, 2001b; Magill et al.,
2001; Breit et al., 2007; Rivlin-Etzion et al., 2010). Similar bursty
pattern has been reported in PD patients when microrecordings
have been done during surgery for the implantation of deep
brain stimulation electrodes (Hutchison et al., 1998; Benazzouz
et al., 2002). According to the classical model of the anatomo-
functional organization of the basal ganglia, the pathological
activity recorded in basal ganglia nuclei has been identified as a
consequence of dopamine depletion in the striatum (Albin et al.,
1989).
In normal physiological conditions, dopamine has long been
known to be a crucial neuromodulator of striatal processing
of cortical informations carried by glutamatergic synapses on
medium spiny neurons, which represents the principal projec-
tion neurons of the striatum. Dopamine excites medium spiny
neurons of the “direct” pathway through dopamine D1 receptors,
while it inhibits striatal neurons of the “indirect” pathway through
dopamine D2 receptors (Alexander and Crutcher, 1990; Surmeier
et al., 2007). In the context of PD, studies of the neuronal activity
in the basal ganglia of MPTP monkeys and 6-OHDA rat models
of the disease suggested that the direct and the indirect pathways
are differentially affected by the loss of dopamine in the striatum.
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The GABAergic inhibitory direct striato-GPi pathway becomes
underactive, whereas the GABAergic projection from the striatum
to the GPe of the indirect pathway becomes overactive, leading
to the reduced activity along the inhibitory GPe-GPi and GPe-
STN pathways. Thus, it is suggested that exaggerated oscillatory
bursts in STN and in GPi may have been secondary to tonic
disinhibition of both structures from GPe after loss of dopamine
in the striatum. However, the role of dopamine depletion in these
extrastraiatal basal ganglia nuclei in the pathophysiology of PD is
still not clearly defined. Nevertheless, in view of the demonstrated
physiologic actions of dopamine on pallidal and STN neuronal
activity as well as the effects on motor behavior of local injection
of dopamine drugs, it is assumed that the loss of pallidal and
subthalamic dopaminergic control would contribute to the motor
symptoms in PD (Rommelfanger and Wichmann, 2010; Wilson
and Bevan, 2011).
The pallidal complex and the STN are innervated by nigral
dopamine fibers, by separate fiber system and also by collaterals
of nigrostriatal fibers. This has been shown in rodents (Lindvall
and Bjorklund, 1979; Debeir et al., 2005; Anaya-Martinez et al.,
2006), in non-human primate (Nobin and Bjorklund, 1973;
Parent and Smith, 1987; Lavoie et al., 1989; Parent et al., 1989;
François et al., 1999; Hedreen, 1999; Jan et al., 2000) and in
human brains (Nobin and Bjorklund, 1973; Cossette et al., 1999;
François et al., 1999; Jan et al., 2000). Dopamine acts via five
receptor subtypes subdivided into two receptor families: D1 (D1
and D5 subtypes) and D2 (D2, D3 and D4 subtypes). All are
prototypic of G-protein-coupled receptors with dopamine D1
receptors being positively linked to adenylate cyclase and D2
receptors had negative coupling to the enzyme (Kebabian and
Calne, 1979). A large number of experimental studies reported
that functional dopamine receptors are expressed in the striatum
and also in the GPe, GPi and STN and that dopamine modulates
their neuronal activity through a variety of mechanisms via pre-
and post-synaptic sites (Smith and Villalba, 2008; Rommelfanger
and Wichmann, 2010).
Dopamine, through D1 and D2 family receptors, in the pallidal
complex and the STN may modulate the motor circuit and
consequently dopamine depletion in these structures may play a
role in the pathophysiology of PD. Lesions of dopamine neurons
in the SNc in rodents and monkeys have been shown to reduce
dopamine levels in GPe, GPi and STN in addition to the striatum
(Parent et al., 1990; François et al., 1999; Jan et al., 2000; Fuchs
and Hauber, 2004).
DOPAMINE DEPLETION IN THE GLOBUS PALLIDUS
Rajput et al. (2008) have recently reported a marked loss of
dopamine in the GPe (−82%) of PD patients with a severe loss
of dopamine in the caudate (−89%) and the putamen (−98.4%).
Based on the conclusions of a previous experimental study (Pifl
et al., 1991), the authors suggested that pallidal dopamine par-
ticipates in the functional compensation against the severe loss
of dopamine in the striatum at the early stage of the disease.
It has been shown that in the MPTP-treated primate model
of parkinsonism in which the animals with stable parkinso-
nian symptoms showed a marked pallidal dopamine depletion,
asymptomatic animals showed normal pallidal dopamine levels
but had very marked striatal dopamine deficit (Pifl et al., 1991).
Similarly, imaging studies using positron emission tomography
in PD patients reported that while patients with severe advanced
stage of the disease had significantly reduced 18F-dopa uptake in
the striatum, GPe and GPi, patients at mild stage of the disease
demonstrated a severely reduced 18F-dopa uptake in the striatum
but normal uptake in GPe and GPi (Whone et al., 2003; Pavese
et al., 2011). Furthermore, an increase in 18F-dopa uptake in
GPi has been reported in early stage PD (Rakshi et al., 1999;
Whone et al., 2003; Moore et al., 2008; Pavese et al., 2011).
Together, these studies postulate that dopamine plays a key role in
the compensatory up-regulation of the nigro-pallidal dopamine
projection in the early stages of PD representing a compen-
satory adaptive mechanism to preserve functionality. In contrary,
dopamine depletion in the two pallidal segments (GPe and GPi)
may participate in the aggravation of motor symptoms in the late
stages of PD.
Studies on the expression of dopamine receptors in the
pallidal complex of parkinsonian brains reported conflicting
data. While some studies found no difference in dopamine
D1R expression in the GPe and GPi (Rinne et al., 1985;
Cortés et al., 1989), others found dopamine D1R expression
unchanged in the GPi and decreased in GPe (Hurley et al.,
2001). Dopamine D2 receptors, including D3 receptors, were
unchanged in both GPe and GPi (Bokobza et al., 1984; Cortés
et al., 1989; Ryoo et al., 1998). The absence of changes in
the expression of D1 and D2 receptors can be explained by
the fact that patients were under dopaminergic medication
before death and that the treatment is likely to normalize the
expression of these receptors. This may be true for the stria-
tum but not for the pallidal complex as in MPTP monkeys,
the expression of dopamine D3 receptors was reduced in the
caudate nucleus but not in the GPe and GPi and that L-Dopa
treatment normalized the hypoexpression of dopamine D3 recep-
tors in the caudate nucleus and increased to a level higher than
normal in GPi without any change in the GPe (Bézard et al.,
2003).
The contribution of pallidal dopamine in the pathophysiology
of PD has also been demonstrated in rodents. Activation of D1 or
D2 dopamine receptors in the GP induced movement facilitation
(Sañudo-Peña and Walker, 1998). In contrast, local blockade of
D1 and/or D2 receptors by intra-pallidal infusions of specific
antagonists induced akinesia in rats (Hauber et al., 1998; Hauber
and Lutz, 1999). Similarly, in rats bearing a unilateral 6-OHDA
lesion, it has been shown that blockade of either dopamine D1 or
D2 receptors reduced apormorphine-induced turnings and that
dopamine infusion into the GP improved motor deficits in the
same animal model (Galvan et al., 2001). Furthermore, we have
recently shown that intra-pallidal injection of 6-OHDA produced
deficits of dopaminergic transmission that caused asymmetrical
motor impairment and reduction of locomotor activity in the rat
(Bouali-Benazzouz et al., 2009; Abedi et al., 2013). Together, these
studies provide arguments that dopamine transmission within
the globus pallidus is necessary to achieve motor control and
that its lack plays a role in the pathophysiology of parkinsonian
motor symptoms, in addition to dopamine depletion in the
striatum.
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DOPAMINE DEPLETION IN THE SUBTHALAMIC NUCLEUS
STN holds a pivotal position in basal ganglia circuitry exert-
ing an excitatory drive on the output structures of the sys-
tem (Albin et al., 1989; Alexander and Crutcher, 1990). The
STN has been shown to play a key role in motor control,
as its hyperactivity with oscillatory bursts has been associated
to parkinsonian motor deficits. The motor symptoms can be
reversed by selective STN lesion or high frequency stimulation
(Bergman et al., 1990; Benazzouz et al., 1993; Limousin et al.,
1995; Krack et al., 2003). Several studies have suggested the
implication of SNc-STN dopaminergic projection in the patho-
physiology of PD. Thus, bilateral infusions of D1 but not D2
receptor antagonists into the STN induced catalepsy in normal
rats (Hauber, 1998) and that activation of D1 receptors resulted
in orofacial dyskinesias in normal and dopamine-depleted rats
(Parry et al., 1994; Mehta et al., 2000). From these studies it
is suggested that dopaminergic agents acting at D1 receptors
have stronger functional and behavioral effects than agents acting
at D2 receptors. Several studies have shown that dopamine is
reduced in the STN in experimental Parkinsonism and also in
patients with PD (Pifl et al., 1990; Hornykiewicz, 1998; François
et al., 2000) and such dopamine loss in the STN may contribute
to increase abnormal neuronal activity. Accordingly, selective
lesions of the dopaminergic fibers located in the STN, by intra-
subthalamic infusion of 6-OHDA, resulted in contralateral muscle
rigidity and ipsilateral turning in response to systemic admin-
istration of DL-methamphetamine (Flores et al., 1993). These
motor deficits could be explained by the fact that 6-OHDA
injection into the STN resulted in retrograde degeneration of
dopamine cell bodies in the lateral part of the SNc (Ni et al.,
2001a) and was at the origin of the significant increase in the
percentage of STN neurons exhibiting burst pattern (Ni et al.,
2001b). These results provide evidence that the degeneration
of SNc-STN dopaminergic projections plays, at least in part,
a role in the development of the pathological burst pattern
of STN neurons and therefore to the manifestation of PD-like
motor deficits. In the same 6-OHDA rat model, it has been
shown that lesions of the SNc dopaminergic cells increased the
level of dopamine D2 receptor mRNA, decreased D3 recep-
tor mRNA levels, and did not induce significant changes in
Dl receptor mRNA in the STN (Flores et al., 1999). Further-
more, several studies have shown that dopamine D5 receptors,
which display a high agonist-independent constitutive activity
in vitro (Tiberi and Caron, 1994; Demchyshyn et al., 2000),
are located in the STN and are able to potentiate burst firing
in STN neurons in in vitro rat brain slices (Baufreton et al.,
2003, 2005). These authors suggested that in the parkinsonian
state, the reduction of dopaminergic transmission in the STN
results in a lack of activation of dopamine D2 receptors, and
as D5 receptors are constitutively active even in the absenc of
dopamine, they contribute to the development of burst discharges
of STN neurons (Baufreton et al., 2005). This assumption has
been demontsrated by our recent in vivo study, in which we
have shown that local microinjection of an inverse agonist of D5
receptors, flupenthixol, reduced burst activity of STN neurons
and therefore improved the motor deficits in the 6-OHDA rat
model of PD (Chetrit et al., 2013). Moreover, STN dopaminergic
afferents have also been suggested to play a relevant role in the
expression of dyskinesias. Indeed, dopamine depletion in the
STN attenuated levodopa-induced dyskinesia in rats bearing a
concomitant lesion of the nigrostriatal pathway (Marin et al.,
2013).
CONCLUSION
While the degeneration of the dopaminergic nigrostriatal pathway
is the hallmark of PD, there is strong evidence about the key role
played by dopamine loss at extrastriatal sites, especially in the pal-
lidal complex and the STN, in the pathophysiology of the disease.
Activation of dopamine receptors in these important basal gan-
glia nuclei modulates their neuronal activity, and consequently
participates in the beneficial effects, and may be in the adverse
effects, of the classical dopaminomimetic antiparkinsonian drugs.
Together, we can assume that dopamine transmission within the
globus pallidus and the STN is necessary to achieve normal motor
control.
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